/ /

  • linkedin
  • Increase Font
  • Sharebar

    Drug, device innovations making strides for glaucoma care in 2017

    Patients may benefit from new drug advances, IOP self-monitoring, MIGS devices

     

     

    Surgery

    Though no significant new devices or procedures were approved in the United States in 2017, two MIGS devices that were cleared by the FDA in 2016 reached the U.S. market (CyPass Micro-Stent, Alcon Laboratories; XEN Glaucoma Treatment System, Allergan). The two devices offer an alternative to the trabecular micro-bypass stent (iStent, Glaukos).

    Each of the devices opens up passages for drainage of aqueous fluid. The CyPass acts as a conduit between the anterior chamber and the supraciliary space. The XEN, composed of gelatin, is implanted through the sclera and connects the anterior chamber to the subconjunctival space.

    By contrast, the iStent bypasses the inner wall of Schlemm’s canal and allows aqueous humor more direct access from the anterior chamber to the collector channels at the outer aspect of Schlemm’s canal.

    Other MIGS devices are also working through trials, and this approach seems to have opened the flow of change in glaucoma surgery.

     

    Andrew Iwach, MD
    e: [email protected]
    Dr. Iwach disclosed financial interests in Alcon Laboratories and Bausch + Lomb.

    Joel S. Schuman, MD
    e: [email protected]
    Dr. Schuman disclosed financial relationships with Aerie Pharmaceuticals,
    Alcon Laboratories, Annexon, Elsevier, lOP Medical, Ocugenix, Opticent Health,
    Pfizer, Shire Pharmaceuticals, Slack Inc./Vindico Medical Education, and
    Zeiss Optical.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results